Karlheinz Theobald

Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany

Winfried März, Franz‐Werner Dippel, Karlheinz Theobald et al. · Atherosclerosis · 2017 · 89 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Systemic Risk Score Evaluation in Ischemic Stroke Patients (SCALA)

Christian Weimar, Michael Goertler, Joachim Röther et al. · Journal of Neurology · 2007 · 44 citations

Medicine, Internal Medicine, Risk Analysis +12

Quality assurance in non-interventional studies

Karlheinz Theobald, Müge Capan, Marlis Herbold et al. · PubMed · 2009 · 32 citations · Full text

Medicine, Pharmacology, Clinical Epidemiology +9

Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland

A. Lebioda, D. Gasche, Franz‐Werner Dippel et al. · Health Economics Review · 2014 · 27 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacology +17

Insulin glulisine, insulin lispro and regular human insulin show comparable end‐organ metabolic effects: an exploratory study

Karl Horvath, Gerlies Bock, Werner Regittnig et al. · Diabetes Obesity and Metabolism · 2007 · 14 citations

Medicine, Endocrinology, Pharmacology +13